For the quarter ending 2026-03-31, RNA had $268,264K increase in cash & cash equivalents over the period. -$33,241K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -16,633 | -237,101 | -174,442 | -273,088 |
| Depreciation | 151 | 1,496 | 1,056 | 1,599 |
| Stock-based compensation expense | 12,213 | 43,419 | 19,024 | 35,395 |
| Amortization of premiums and discounts on marketable securities, net | - | 1,487 | 2,405 | 8,632 |
| Loss on disposal of property and equipment | - | -57 | -83 | - |
| Non-cash operating lease costs | 841 | 1,570 | 1,027 | 1,645 |
| Collaboration receivable | 15,000 | - | - | - |
| Prepaid and other assets | 1,043 | 2,551 | 24,205 | 116,078 |
| Accrued expenses and other liabilities | - | 23,711 | 35,140 | 31,891 |
| Other current assets | -1,208 | - | - | - |
| Accounts payable | -3,591 | 2,687 | 5,782 | -4,670 |
| Accrued liabilities | -1,995 | - | - | - |
| Accrued compensation | -15,838 | - | - | 14,782 |
| Operating right-of-use assets and lease liabilities, net | - | -715 | -2,031 | - |
| Lease liabilities | 890 | - | - | -1,919 |
| Deferred revenues | -4,635 | -859 | -2,339 | -5,420 |
| Other long-term liabilities | -574 | - | - | - |
| Net cash used in operating activities | -31,143 | -169,773 | -156,173 | -324,495 |
| Purchases of marketable securities | - | 9,998 | 853,603 | 243,271 |
| Proceeds from maturities of marketable securities | - | 223,618 | 269,564 | 593,040 |
| Purchases of property and equipment | 2,098 | 5,511 | 712 | 7,096 |
| Tenant improvements capitalized to right-of-use assets | - | 891 | 3,175 | - |
| Net cash used in investing activities | -2,098 | 207,218 | -587,926 | 342,673 |
| Proceeds from issuance of common stock in public offerings, net of issuance costs | - | -538 | 837,420 | 0 |
| Proceeds from issuance of common stock in private placements, net of issuance costs and allocation to deferred revenues (note 5) | - | 0 | 0 | 0 |
| Proceeds from issuance of pre-funded warrants in a private placement, net of issuance costs | - | 0 | 0 | 0 |
| Proceeds from the issuance of common stock under employee incentive equity plans | - | 7,861 | 12,946 | 5,710 |
| Payments for taxes related to net share settlement of equity awards | - | 12,409 | - | - |
| Net transfers from former parent | 301,505 | - | - | - |
| Net cash provided by financing activities | 301,505 | -5,086 | 850,366 | 5,710 |
| Effect of exchange rate on cash, cash equivalents and restricted cash | - | -1 | -16 | 154 |
| Net increase in cash and cash equivalents | 268,264 | 32,358 | 106,251 | 24,042 |
| Cash, cash equivalents and restricted cash, at beginning of period | 0 | 352,956 | 222,663 | - |
| Cash, cash equivalents and restricted cash, at end of period | 268,264 | 385,314 | 352,956 | - |
Avidity Biosciences, Inc. (RNA)
Avidity Biosciences, Inc. (RNA)